Last reviewed · How we verify
NCT03910907
Comparison of Standard of Care Guidelines for Mycoplasma Genitalium Infections Among Men With Non-gonococcal Urethritis
trial testing Comparison of two standard of care regimens in Mycoplasma Genitalium Infection in 10 participants. Terminated before completion.
20 March 2020
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 19 November 2019 |
| Primary completion | 20 March 2020 |
| Estimated completion | 20 March 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Comparison of two standard of care regimens — full drug profile →
Conditions studied
- Mycoplasma Genitalium Infection — all drugs for Mycoplasma Genitalium Infection →
Sponsor
University of Alabama at Birmingham
Who can join
Adults 18 to 99, male only, with Mycoplasma Genitalium Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this protocol is to determine the difference in clearance of Mycoplasma genitalium (MG) when using the Australian management protocol versus the current Centers of Disease Control (CDC) treatment guidelines for US standard of care (SOC), to determine the proportion of men from the Deep South, with NGU attributable to MG, and to determine the proportion of MG cases that harbor the macrolide-resistance associated with mutation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03910907
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Comparison of two standard of care regimens
Trials testing the same drug.
- NCT06838689 — Participatory Approaches to Qualitative Research (PAQ): Comparing Two Approaches to Patient, Public and Clinician Involv · NA · recruiting
Other recruiting trials for Mycoplasma Genitalium Infection
Currently open trials in the same condition.
- NCT06793605 — Community Burden of MG Infection · recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03910907 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 2 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03910907.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing